pharmaphorum1h
Ensuring compliance - The Functional Point of Contact (FPOC) story
As has been widely acknowledged, one of the most meaningful steps a business can take is to establish a single point of ...
Pharmabiz5h
Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer
Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...
pharmaphorum15h
Genentech buys Regor's next-gen CDK inhibitors for $850M
Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the ...
Roche turns to a startup in search for new breast cancer drugs
The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to ...
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales.
The Pharma Letter18h
Genentech to acquire Regor's next-gen CDK inhibitors portfolio
Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...
ENDPOINTS NEWS22h
Roche buys Re­gor’s CDK in­hibitors for $850M up­front amid push to de­vel­op 20 ‘trans­for­ma­tive’ med­i­cines
Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...